HURA Form 4 reports acquisition/exercise transactions

List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA.

Accepted by SEC EDGAR 02/17/2026 - 04:16 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.

Insider Trade Summary

Grant/Award: 156,240 shares

Grant/Award 1 txn

Insider List Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	156,240	$0.00	$0.00
Holding	Options (Right to Buy)	--	--	--

Holdings After Transaction: Options (Right to Buy) — 207,515 contracts for 51,275 underlying shares (Direct)

Holdings Before and After: Options (Right to Buy), 51,275 to 207,515 contracts (Direct)

Footnotes (2)

1. F1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
2. F2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TuHURA Biosciences (HURA) director Alan List report on this Form 4?

Alan List reported receiving an annual stock option grant. He was awarded 156,240 options to buy TuHURA common stock at $1.29 per share, expiring in 2036, as equity-based compensation under the company’s 2024 Equity Incentive Plan.

What are the key terms of Alan List’s new stock options from TuHURA (HURA)?

The new grant covers 156,240 options with a $1.29 exercise price per share. These options expire on February 12, 2036 and were issued under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan as an annual director award.

How do Alan List’s TuHURA (HURA) options vest over time?

The newly granted 156,240 options vest in three equal installments. One-third becomes exercisable on each of the first, second, and third anniversaries of February 12, 2026, aligning the director’s compensation with multi‑year service to the company.

What prior stock options for TuHURA (HURA) does Alan List hold?

Alan List also holds a prior annual option grant of 51,275 options with a $4.11 exercise price. These options were granted on January 2, 2025 and expire on January 2, 2035, with similar three‑year vesting based on annual anniversaries.

Is Alan List’s Form 4 for TuHURA (HURA) a purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open‑market share purchase. The transaction code indicates a grant or award of 156,240 stock options under TuHURA’s 2024 Equity Incentive Plan as part of his role as a director.

What role does Alan List hold at TuHURA Biosciences (HURA)?

Alan List is reported as a director of TuHURA Biosciences, Inc. His Form 4 filing details stock option awards tied to his director service, including a new grant of 156,240 options and a previously granted 51,275-option award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

List Alan

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.29	02/12/2026(1)		A		156,240		(1)	02/12/2036	Common Stock	156,240	$0	156,240	D
Options (Right to Buy)	$4.11							(2)	01/02/2035	Common Stock	51,275		51,275	D

Explanation of Responses:

1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

	/s/ Dan Dearborn as Power of Attorney for Alan List	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.